204P - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure Invasive Lobular breast Carcinoma (ILC): prel...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Early Stage
Breast Cancer
Presenter Luisa Carbognin
Citation Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362
Authors L. Carbognin1, M. Brunelli2, E. Manfrin2, A. Caliò2, I. Sperduti3, M.V. Dieci4, G. Griguolo4, V. Guarneri4, R. Nortilli1, S. Pilotto1, E. Fiorio5, V. Parolin5, E. Orvieto6, F. Pellini7, G.P. Pollini7, P.F. Conte8, A. Scarpa2, G. Tortora1, E. Bria1
  • 1Medical Oncology, University of Verona, 37134 - Verona/IT
  • 2Department Of Pathology And Diagnostics,, University and Hospital Trust of Verona, Verona/IT
  • 3Biostatistics, Regina Elena National Cancer Institute, Rome/IT
  • 4Department Of Surgery, Oncology And Gastroenterology, University of Padova, 35128 - Padova/IT
  • 5Oncology, AOU Integrata Verona, 37126 - Verona/IT
  • 6Department Of Surgery, Oncology And Gastroenterology, Istituto Oncologico Veneto, 35128 - Padova/IT
  • 7Breast Surgery, AOU Integrata Verona, 37126 - Verona/IT
  • 8Medical And Experimental Oncology Department, Medical Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT

Abstract

Background

The biological drivers of prognosis for pure ILC are not entirely clear. The aim of this analysis was to investigate the molecular and immune-related portrait of prognostic outliers to identify different patterns of expression associated with prognosis and potentially druggable.

Methods

Clinical-pathological multi-center data of resected early-stage pure ILC patients (pts) were correlated to disease-free and overall-survival (DFS/OS). A continuous score was derived according to multivariate Hazard Ratios, in order to derive a 3-class model (Poor/Intermediate/Good Prognosis). IHC (for Ph-mTOR, CDK6, PD-L1), FISH (for ESR1, Ph-mTOR, CDK4, PD-L1) and H&E evaluation (for stromal Tumor Infiltrating Lymphocytes, sTILs) were performed upon pts at Poor and Good Prognosis. Odds Ratio (OR) with 95% CIs for the risk of association with prognostic class of biomarkers was determined.

Results

Data from 457 pts were gathered (median age 57 years, median follow: 75 months). The 3-class cross-validated model significantly differentiated DFS and OS (p 

Conclusions

Despite unpowered, these preliminary data suggest that Poor and Good prognosis are potentially associated to differential expression of a cluster of biomarkers: ESR1 deletion, CDK4 gain, CDK6 and ph-mTOR over-expression versus high sTILs, PD-L1 positive, ESR1 gain and ph-mTOR deletion, respectively.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

University of Verona

Funding

None

Disclosure

All authors have declared no conflicts of interest.